Affymax(R) to Present at Thomas Weisel Partners Healthcare Conference 2007.PALO ALTO Palo Alto, city, California Palo Alto (păl`ō ăl`tō), city (1990 pop. 55,900), Santa Clara co., W Calif.; inc. 1894. Although primarily residential, Palo Alto has aerospace, electronics, and advanced research industries. , Calif. -- Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene M. Morris, the company's president and chief executive officer, will present at the Thomas Weisel Partners Thomas Weisel Partners Group, Inc. (NASDAQ: TWPG), often shortened to just TWP or TWeisel, is a U.S. middle-market and growth focused investment banking firm based in San Francisco, California. Healthcare Conference 2007 on Thursday, September 6, at 11:30 a.m. Eastern Time in Boston. A live webcast of the presentation will be available on the Investors section of the company's website at www.affymax.com. A replay will also be available for 30 days following the presentation. About Affymax, Inc. Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's lead product candidate, Hematide[TM], is currently in Phase 3 clinical trial phase 3 clinical trial Phase 3 study. See Phase study. stage for the treatment of anemia associated with chronic renal failure chronic renal failure Chronic kidney failure Nephrology A slow decline in renal function, which may be 2º to chronic HTN, DM, CHF, SLE, or sickle cell anemia and, if extreme, leads to ESRD, mandating kidney dialysis; an abrupt decline in renal function may be and in clinical trials for the treatment of anemia in cancer patients. For additional information, please visit www.affymax.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion